8-K: ImmunityBio Q2 Revenue Jumps 60%, ANKTIVA Sales Soar

ImmunityBio reported a 60% increase in Q2 2025 revenue driven by strong ANKTIVA sales, alongside progress in clinical trials and a recent equity financing.

Summary

• Q2 2025 revenue reached $26.4 million, marking a 60% increase from Q1 2025.
• Year-to-date sales for the first half of 2025 were approximately $43 million, with ANKTIVA unit sales volume growing 246% since J-code approval compared to the second half of 2024.
• The cash, cash equivalents, and marketable securities stood at $153.7 million as of June 30, 2025, supplemented by an additional $80 million equity financing closed in July 2025, with warrants potentially yielding up to $96.0 million in gross proceeds.
• Net loss attributable to common stockholders for Q2 2025 was $92.6 million, a reduction from $134.6 million in Q2 2024.
• For the six months ended June 30, 2025, net loss was $222.2 million, down from $268.7 million in the prior year period.
• ImmunityBio launched ResQ201A, a randomized controlled trial for Non-Small Cell Lung Cancer (NSCLC) in the U.S., and submitted clinical trial applications in the EU and UK, with Canada expected in early Q3 2025 and Asia plans underway.
• The U.S. FDA's Division of Non-Malignant Hematology was supportive of findings from the lymphopenia program but indicated additional time is needed to finalize the development plan; an Expanded Access Program (EAP) has been activated for solid tumors with low absolute lymphocyte counts (ALC < 1,000/L).
• Full enrollment was achieved in the randomized National Cancer Institute (NCI) cancer prevention clinical trial for Lynch Syndrome, involving 186 patients using ANKTIVA in combination with adenovirus vaccine.
• The UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved marketing authorization for ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with CIS, with or without papillary tumors.
• The FDA issued a Refuse to File (RTF) notice in May 2025 for the papillary-only NMIBC supplemental Biologics License Application (sBLA), requiring a randomized controlled trial (RCT) against chemotherapy, contrary to prior advice; ImmunityBio is re-evaluating its approach, potentially amending the filing with new data and committing to an RCT.
• An application was submitted to the National Comprehensive Cancer Network (NCCN) to expand BCG-unresponsive NMIBC guidelines to include papillary-only disease, with review expected at its August 2025 meeting.

Sentiment

Score: 7

Explanation: The company shows strong commercial growth for its key product ANKTIVA and a significant reduction in net loss, indicating improving financial health. Positive clinical trial progress and a new UK approval are also strong points. However, the FDA's Refuse to File for a key indication and the requirement for a new RCT introduce regulatory uncertainty and potential delays for that specific program. The overall sentiment is positive due to commercial momentum and financial improvement, but tempered by regulatory hurdles.

Positives

• Product revenue increased significantly, with Q2 2025 revenue of $26.4 million, up 60% from Q1 2025.
• Strong commercial traction for ANKTIVA, evidenced by year-to-date sales of $42.9 million and a 246% increase in unit sales volume since J-code approval.
• Net loss was substantially reduced to $92.6 million in Q2 2025 from $134.6 million in Q2 2024, and to $222.2 million for the first half of 2025 from $268.7 million in the prior year period.
• The company's cash position was strengthened to $153.7 million as of June 30, 2025, further bolstered by an $80 million equity financing in July 2025.
• ANKTIVA received marketing authorization from the UK MHRA for BCG-unresponsive NMIBC, opening a new international market.
• Initiated a randomized controlled trial (ResQ201A) for second-line lung cancer in the U.S. and is expanding clinical trial applications globally.
• The FDA expressed support for the underlying science and findings of the lymphopenia program, indicating a desire for an efficient path to approval.
• Full enrollment was achieved in the NCI cancer prevention clinical trial for Lynch Syndrome, demonstrating progress in a key study.

Negatives

• The FDA issued a Refuse to File (RTF) notice for the papillary-only NMIBC sBLA, requiring a randomized controlled trial (RCT) against chemotherapy, which contradicts prior FDA advice and introduces a significant regulatory hurdle and potential delay for this indication.
• Despite FDA support for the lymphopenia program, additional time is required to finalize the appropriate development plan, indicating a slower-than-desired progression towards approval.
• The company continues to incur substantial net losses, with $92.6 million in Q2 2025 and $222.2 million for the first half of 2025, highlighting ongoing operational costs despite revenue growth.

Risks

• Uncertainties regarding the FDA and other regulatory agencies' submission, filing, and review processes and their timing.
• Risks and uncertainties related to commercial launch execution, success, and timing.
• No assurance that the RMAT designation will lead to accelerated review or approval.
• Risks and uncertainties concerning participation, enrollment, and potential results from expanded access clinical investigation programs.
• Uncertainty whether clinical trials will result in registrational pathways or if clinical trial data will be accepted by regulatory agencies.
• Uncertainty regarding the NCCN's review and approval of the company's guidelines submission on the anticipated timeline or at all.
• Risks and uncertainties related to market access initiatives and their timing.
• Uncertainty whether the FDA will permit the resubmission of the NMIBC papillary sBLA and the specific requirements for such a submission.
• No assurance that the FDA will ultimately approve the sBLA or other submissions in a timely manner, or at all.
• Risks and uncertainties due to changes in personnel at the FDA and limited resources, potentially leading to delays.
• The ability to fund ongoing and anticipated clinical trials.
• The ability to continue planned preclinical and clinical development, patient enrollment, and planned regulatory submissions.
• Potential delays in product availability and regulatory approvals.
• Risks and uncertainties associated with third-party collaborations and agreements, including with Serum Institute of India.
• The ability to retain and hire key personnel.
• The ability to obtain additional financing to fund operations and complete the development and commercialization of product candidates.
• Potential product shortages or manufacturing disruptions that may impact product availability and timing.
• The ability to successfully commercialize approved products and product candidates.
• The ability to scale manufacturing and commercial supply operations for approved and future products.
• The ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for product candidates and technologies.

Future Outlook

ImmunityBio plans global expansion of key clinical trials for BCG-naive NMIBC and second-line lung cancer. The company is initiating enrollment across multiple trials to validate its novel lymphopenia rescue agent, aiming to prolong survival across various tumor types. Following UK MHRA approval, ImmunityBio is actively evaluating its go-to-market strategy for ANKTIVA in this initial global market. For papillary-only NMIBC, the company is re-evaluating its regulatory approach, considering amending the initial sBLA filing with new data or withdrawing it and committing to initiate a randomized controlled trial against chemotherapy.

Management Comments

• "ANKTIVA continues to deliver clinical results and promising commercial potential for ImmunityBio. We’re seeing robust demand across U.S. urology practices of all sizes, driven in part by ANKTIVA’s ease of storage and administration. With commercial authorization now in place in the UK, we’re actively evaluating our go-to-market strategy for this important initial global market. In parallel, our recombinant BCG (rBCG) therapeutic has been administered safely to more than 150 patients to date in the United States under the expanded access protocol, helping urologists address the ongoing BCG shortage in the U.S. The recent equity financing further strengthens our balance sheet and enables us to accelerate key studies." Richard Adcock, President and CEO of ImmunityBio.
• "Our goal has always been to use our innovative science to attack a broad range of cancers, and we are deeply committed to this goal in order to meet the urgent needs of millions of patients. To that end, we’ve begun global expansion of key clinical trials, including those for BCG-naive NMIBC and second-line lung cancer. In addition, we’ve initiated enrollment across multiple trials to validate our novel lymphopenia rescue agent in prolonging duration of survival across multiple tumor types—a critical effort to address this life-threatening immune deficiency, and is often triggered by chemotherapy, radiation, or some immunotherapies." Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio.

Industry Context

ImmunityBio's recombinant BCG (rBCG) therapeutic directly addresses the critical ongoing BCG shortage in the U.S., a significant challenge for bladder cancer treatment. The company's focus on lymphopenia, a life-threatening immune deficiency often triggered by standard cancer therapies, highlights its commitment to addressing unmet medical needs in oncology. The expansion of ANKTIVA into the UK market and the initiation of global clinical trials align with broader industry trends of biopharmaceutical companies seeking international market access and diversifying their clinical pipelines. The FDA's requirement for a randomized controlled trial against chemotherapy for papillary-only NMIBC underscores the agency's stringent regulatory standards, particularly when existing treatment options are available, influencing development strategies across the industry.

Comparison to Industry Standards

• ImmunityBio presented new data for papillary-only NMIBC from its QUILT-3.032 trial, demonstrating long-term (36-month) progression-free survival and bladder sparing with ANKTIVA in combination with BCG.
• The company presented newly published real-world data showing that ANKTIVA in combination with BCG led to improved outcomes of progression-free survival and cystectomy avoidance at 36-months compared to chemotherapy.
• The results to date of ANKTIVA in combination with BCG are stated to represent the longest duration of follow-up with the longest duration of bladder sparing in these subjects, suggesting a potentially superior outcome compared to existing treatments, though specific comparable companies or projects are not named in the filing.

Related Party Transactions

• Interest expense related party of $(15,474) thousand for Q2 2025 and $(30,787) thousand for 1H 2025.
• Research and development related parties expense of $2,806 thousand for Q2 2025 and $5,064 thousand for 1H 2025.
• Selling, general and administrative related parties expense of $476 thousand for Q2 2025 and $1,153 thousand for 1H 2025.
• Total related-party debt of $492,084 thousand as of June 30, 2025.
• Change in fair value of warrant and derivative liabilities, and related-party convertible notes of $6,989 thousand for Q2 2025 and $(30,463) thousand for 1H 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, reduced net loss, and successful capital raise. Potential negative impact from regulatory setbacks (FDA RTF) and associated delays for papillary-only NMIBC.
• Patients: Positive impact from ANKTIVA's commercial availability and continued clinical development for various cancers (NSCLC, lymphopenia, Lynch Syndrome), and the rBCG EAP addressing BCG shortage.
• Employees: Potential positive impact from growing sales and marketing activities, indicated by higher stock-based compensation, recruiting, training, salaries, benefits, commissions, and travel expenses in SG&A for 1H 2025.
• Customers (Urology Practices): Positive impact from robust demand for ANKTIVA and its ease of storage/administration, as well as the rBCG EAP addressing the BCG shortage.

Next Steps

• Submit clinical trial application for ResQ201A in Canada in early Q3 2025, with plans for Asia.
• Finalize appropriate development plan for the lymphopenia program with the FDA.
• Re-evaluate regulatory approach for papillary-only NMIBC, potentially amending the initial sBLA filing with new data or withdrawing it and committing to initiate an RCT.
• NCCN expected to review the submission for expansion of BCG-unresponsive NMIBC guidelines in August 2025.
• Actively evaluate go-to-market strategy for ANKTIVA in the UK.

Key Dates

Recommendation

While ImmunityBio demonstrates strong commercial growth for ANKTIVA and a significant reduction in net losses, indicating improving operational efficiency and market penetration, the FDA's Refuse to File for the papillary-only NMIBC sBLA introduces a notable regulatory hurdle and potential delays for a key indication. The need for a randomized controlled trial against chemotherapy for this specific indication adds uncertainty and extends the timeline for potential approval. The recent capital raise strengthens the balance sheet, but the ongoing net losses and the need for further clinical trials suggest continued cash burn. Given the strong commercial performance balanced against the regulatory setback and ongoing development costs, a "hold" recommendation is appropriate, advising investors to monitor the resolution of the FDA's RTF and the progress of ongoing trials.

Keywords

ImmunityBio, IBRX, ANKTIVA, Biotechnology, Immunotherapy, Cancer Treatment, NMIBC, Non-Small Cell Lung Cancer, Lymphopenia, Lynch Syndrome, Clinical Trials, FDA Approval, MHRA Approval, Q2 Earnings, Pharmaceuticals, Oncology